RegeneRx Biopharmaceuticals Inc (OTCMKTS:RGRX) Stock Resumes Another Round Of Sell-Off
Clinical stage medicine developer RegeneRx Biopharmaceuticals Inc (OTCMKTS:RGRX), which is primarily concerned with tissue protection and repair products, saw its stock take a beating on Wednesday. The stock tanked by as much as 7% yesterday after the company announced the results from an independent research paper which indentified Thymosin Beta 4 or TB4 as a possible treatment for critical kidney injuries and for possibly reducing the mortality among patients who…